Skip Navigation



Schizophrenia Bulletin Advance Access published online on July 7, 2007
Schizophrenia Bulletin, doi:10.1093/schbul/sbm074
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
33/5/1100    most recent
sbm074v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Gray, J. A.
Right arrow Articles by Roth, B. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gray, J. A.
Right arrow Articles by Roth, B. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org.

Molecular Targets for Treating Cognitive Dysfunction in Schizophrenia

John A. Gray2 and Bryan L. Roth1,3
2 Department of Psychiatry, University of California, San Francisco, CA
3 Department of Pharmacology, University of North Carolina School of Medicine, 8032 Burnett-Womack, CB # 7365, Chapel Hill, NC 27599-7365

1 To whom correspondence should be addressed; tel: 919-966-7535, fax: 919-966-5640, e-mail: bryan_roth{at}med.unc.edu.

Cognitive impairment is a core feature of schizophrenia as deficits are present in the majority of patients, frequently precede the onset of other positive symptoms, persist even with successful treatment of positive symptoms, and account for a significant portion of functional impairment in schizophrenia. While the atypical antipsychotics have produced incremental improvements in the cognitive function of patients with schizophrenia, overall treatment remains inadequate. In recent years, there has been an increased interest in developing novel strategies for treating the cognitive deficits in schizophrenia, focusing on ameliorating impairments in working memory, attention, and social cognition. Here we review various molecular targets that are actively being explored for potential drug discovery efforts in schizophrenia and cognition. These molecular targets include dopamine receptors in the prefrontal cortex, nicotinic and muscarinic acetylcholine receptors, the glutamatergic excitatory synapse, various serotonin receptors, and the {gamma}-aminobutyric acid (GABA) system.

Keywords: serotonin / dopamine / glutamate / NMDA / acetylcholine / GABA


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
K. A. Jones, D. P. Srivastava, J. A. Allen, R. T. Strachan, B. L. Roth, and P. Penzes
Rapid modulation of spine morphology by the 5-HT2A serotonin receptor through kalirin-7 signaling
PNAS, November 17, 2009; 106(46): 19575 - 19580.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
J. D. Ragland, A. R. Laird, C. Ranganath, R. S. Blumenfeld, S. M. Gonzales, and D. C. Glahn
Prefrontal Activation Deficits During Episodic Memory in Schizophrenia
Am J Psychiatry, August 1, 2009; 166(8): 863 - 874.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
S. Vale
Current Management of the Cognitive Dysfunction in Parkinson's Disease: How Far Have We Come?
Experimental Biology and Medicine, August 1, 2008; 233(8): 941 - 951.
[Abstract] [Full Text] [PDF]

Home page
 Schizophr BullHome page
E. Ivleva, G. Thaker, and C. A. Tamminga
Comparing Genes and Phenomenology in the Major Psychoses: Schizophrenia and Bipolar 1 Disorder
Schizophr Bull, July 1, 2008; 34(4): 734 - 742.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.